SpiderRock Advisors’s AbbVie ABBV Stock Holding History

SpiderRock Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Hold	–	-$477K	–	15
2017 Q3	–	Hold	–	–	–	45
2017 Q2	–	Hold	–	–	–	100
2017 Q1	–	Hold	–	–	–	282

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

SpiderRock Advisors's ABBV Position: Q3 2024 in Review

SpiderRock Advisors increased its AbbVie (ABBV) stake by 19% in Q3 2024, buying an estimated $8.95M and bringing the position to 294,518 shares worth $58.2M. The position accounts for 0.93% of the portfolio, ranked #18.

SpiderRock Advisors first reported a position in ABBV in Q1 2024 and has held it in 3 quarters since. 3,498 funds tracked by Wall St. Rank hold ABBV as of Q3 2024.

SpiderRock Advisors held 294,518 shares of AbbVie worth $58.2M as of Q3 2024.
SpiderRock Advisors bought 47,954 AbbVie shares in Q3 2024, an estimated $8.95M.
AbbVie made up 0.93% of SpiderRock Advisors's portfolio in Q3 2024, its #18 holding.
SpiderRock Advisors first reported a position in AbbVie in Q1 2024 and has held it in 3 quarters since.
3,498 funds tracked by Wall St. Rank held AbbVie as of Q3 2024.

Based on SpiderRock Advisors's 13F filing for Q3 2024, filed 1 Nov 2024.